Skip to main content
Erschienen in: Current Neurology and Neuroscience Reports 5/2011

01.10.2011

Gait Abnormalities in Multiple Sclerosis: Pathogenesis, Evaluation, and Advances in Treatment

verfasst von: Michelle H. Cameron, Joanne M. Wagner

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system characterized by episodic decline in various neurologic functions. Gait dysfunction in MS is distinguished by decreased gait speed, walking endurance, step length, cadence and joint motion, as well as increased metabolic cost of walking and increased variability of gait. Standardized clinical, timed, and patient-based measures can identify MS patients with gait dysfunction, and observational gait analysis, instrumented walkways, or three-dimensional gait analysis can help determine which problem underlies their gait dysfunction to help direct effective treatment. Exercise may ameliorate all types of gait dysfunction. In addition, gait dysfunction due to weakness may be alleviated by orthoses or functional electrical stimulation; gait dysfunction due to spasticity may be relieved by oral, intrathecal, or intramuscular medications. Assistive devices and balance training may reduce gait dysfunction from imbalance, and dalfampridine may accelerate gait in people with MS who walk slowly.
Literatur
1.
Zurück zum Zitat Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–52.PubMed Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–52.PubMed
2.
Zurück zum Zitat Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler. 1999;5:244–50.PubMed Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler. 1999;5:244–50.PubMed
3.
Zurück zum Zitat • Givon U, Zeilig G, Achiron A. Gait analysis in multiple sclerosis: characterization of temporal-spatial parameters using GAITRite functional ambulation system. Gait Posture 2009;29:138–42. This study demonstrates that instrumented walkways can be used to characterize the spatiotemporal characteristics of gait and that specific gait patterns are associated with certain EDSS functional scores.PubMedCrossRef • Givon U, Zeilig G, Achiron A. Gait analysis in multiple sclerosis: characterization of temporal-spatial parameters using GAITRite functional ambulation system. Gait Posture 2009;29:138–42. This study demonstrates that instrumented walkways can be used to characterize the spatiotemporal characteristics of gait and that specific gait patterns are associated with certain EDSS functional scores.PubMedCrossRef
4.
Zurück zum Zitat Martin CL, Phillips BA, Kilpatrick TJ, et al. Gait and balance impairment in early multiple sclerosis in the absence of clinical disability. Mult Scler. 2006;12:620–8.PubMedCrossRef Martin CL, Phillips BA, Kilpatrick TJ, et al. Gait and balance impairment in early multiple sclerosis in the absence of clinical disability. Mult Scler. 2006;12:620–8.PubMedCrossRef
5.
Zurück zum Zitat Thoumie P, Lamotte D, Cantalloube S, Faucher M, Amarenco G. Motor determinants of gait in 100 ambulatory patients with multiple sclerosis. Mult Scler. 2005;11:485–91.PubMedCrossRef Thoumie P, Lamotte D, Cantalloube S, Faucher M, Amarenco G. Motor determinants of gait in 100 ambulatory patients with multiple sclerosis. Mult Scler. 2005;11:485–91.PubMedCrossRef
6.
Zurück zum Zitat Gehlsen G, Beekman K, Assmann N, et al. Gait characteristics in multiple sclerosis: progressive changes and effects of exercise on parameters. Arch Phys Med Rehabil. 1986;67:536–9.PubMed Gehlsen G, Beekman K, Assmann N, et al. Gait characteristics in multiple sclerosis: progressive changes and effects of exercise on parameters. Arch Phys Med Rehabil. 1986;67:536–9.PubMed
7.
Zurück zum Zitat Crenshaw SJ, Royer TD, Richards JG, Hudson DJ. Gait variability in people with multiple sclerosis. Mult Scler. 2006;12:613–9.PubMedCrossRef Crenshaw SJ, Royer TD, Richards JG, Hudson DJ. Gait variability in people with multiple sclerosis. Mult Scler. 2006;12:613–9.PubMedCrossRef
8.
Zurück zum Zitat Remelius JG, Hamill J, Kent-Braun J, Van Emmerik RE. Gait initiation in multiple sclerosis. Motor Control. 2008;12:93–108.PubMed Remelius JG, Hamill J, Kent-Braun J, Van Emmerik RE. Gait initiation in multiple sclerosis. Motor Control. 2008;12:93–108.PubMed
9.
Zurück zum Zitat Savci S, Inal-Ince D, Arikan H, et al. Six-minute walk distance as a measure of functional exercise capacity in multiple sclerosis. Disabil Rehabil. 2005;27:1365–71.PubMedCrossRef Savci S, Inal-Ince D, Arikan H, et al. Six-minute walk distance as a measure of functional exercise capacity in multiple sclerosis. Disabil Rehabil. 2005;27:1365–71.PubMedCrossRef
10.
Zurück zum Zitat Franceschini M, Rampello A, Bovolenta F, et al. Cost of walking, exertional dyspnoea and fatigue in individuals with multiple sclerosis not requiring assistive devices. J Rehabil Med. 2010;42:719–23.PubMedCrossRef Franceschini M, Rampello A, Bovolenta F, et al. Cost of walking, exertional dyspnoea and fatigue in individuals with multiple sclerosis not requiring assistive devices. J Rehabil Med. 2010;42:719–23.PubMedCrossRef
11.
Zurück zum Zitat Gijbels D, Alders G, Van Hoof E, et al. Predicting habitual walking performance in multiple sclerosis: relevance of capacity and self-report measures. Mult Scler. 2010;16:618–26.PubMedCrossRef Gijbels D, Alders G, Van Hoof E, et al. Predicting habitual walking performance in multiple sclerosis: relevance of capacity and self-report measures. Mult Scler. 2010;16:618–26.PubMedCrossRef
12.
Zurück zum Zitat Hamilton F, Rochester L, Paul L, et al. Walking and talking: an investigation of cognitive-motor dual tasking in multiple sclerosis. Mult Scler. 2009;15:1215–27.PubMedCrossRef Hamilton F, Rochester L, Paul L, et al. Walking and talking: an investigation of cognitive-motor dual tasking in multiple sclerosis. Mult Scler. 2009;15:1215–27.PubMedCrossRef
13.
Zurück zum Zitat Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983;308:173–80.PubMedCrossRef Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983;308:173–80.PubMedCrossRef
14.
Zurück zum Zitat Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122:871–82.PubMedCrossRef Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122:871–82.PubMedCrossRef
15.
Zurück zum Zitat Goldman MD, Marrie RA, Cohen JA. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler. 2008;14:383–90.PubMedCrossRef Goldman MD, Marrie RA, Cohen JA. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler. 2008;14:383–90.PubMedCrossRef
16.
Zurück zum Zitat Drake AS, Weinstock-Guttman B, Morrow SA, et al. Psychometrics and normative data for the multiple sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Mult Scler. 2010;16:228–37.PubMedCrossRef Drake AS, Weinstock-Guttman B, Morrow SA, et al. Psychometrics and normative data for the multiple sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Mult Scler. 2010;16:228–37.PubMedCrossRef
17.
Zurück zum Zitat Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology. 2003;60:31–6.PubMed Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology. 2003;60:31–6.PubMed
18.
Zurück zum Zitat Sharrack B, Hughes RA, Soudain S, Dunn G. The psychometric properties of clinical rating scales used in multiple sclerosis. Brain. 1999;122:141–59.PubMedCrossRef Sharrack B, Hughes RA, Soudain S, Dunn G. The psychometric properties of clinical rating scales used in multiple sclerosis. Brain. 1999;122:141–59.PubMedCrossRef
19.
Zurück zum Zitat McGuigan C, Hutchinson M. Confirming the validity and responsiveness of the Multiple Sclerosis Walking Scale-12 (MSWS-12). Neurology. 2004;62:2103–5.PubMed McGuigan C, Hutchinson M. Confirming the validity and responsiveness of the Multiple Sclerosis Walking Scale-12 (MSWS-12). Neurology. 2004;62:2103–5.PubMed
20.
Zurück zum Zitat Krebs DE, Edelstein JE, Fishman S. Reliability of observational kinematic gait analysis. Phys Ther. 1985;65:1027–33.PubMed Krebs DE, Edelstein JE, Fishman S. Reliability of observational kinematic gait analysis. Phys Ther. 1985;65:1027–33.PubMed
21.
Zurück zum Zitat Brunnekreef JJ, van Uden CJ, van Moorsel S, Kooloos JG. Reliability of videotaped observational gait analysis in patients with orthopedic impairments. BMC Musculoskelet Disord. 2005;6:17.PubMedCrossRef Brunnekreef JJ, van Uden CJ, van Moorsel S, Kooloos JG. Reliability of videotaped observational gait analysis in patients with orthopedic impairments. BMC Musculoskelet Disord. 2005;6:17.PubMedCrossRef
22.
Zurück zum Zitat Lord SE, Halligan PW, Wade DT. Visual gait analysis: the development of a clinical assessment and scale. Clin Rehabil. 1998;12:107–19.PubMedCrossRef Lord SE, Halligan PW, Wade DT. Visual gait analysis: the development of a clinical assessment and scale. Clin Rehabil. 1998;12:107–19.PubMedCrossRef
23.
Zurück zum Zitat van Uden CJ, Besser MP. Test–retest reliability of temporal and spatial gait characteristics measured with an instrumented walkway system (GAITRite). BMC Musculoskelet Disord. 2004;5:13.PubMedCrossRef van Uden CJ, Besser MP. Test–retest reliability of temporal and spatial gait characteristics measured with an instrumented walkway system (GAITRite). BMC Musculoskelet Disord. 2004;5:13.PubMedCrossRef
24.
Zurück zum Zitat Dalgas U, Stenager E, Jakobsen J, et al. Resistance training improves muscle strength and functional capacity in multiple sclerosis. Neurology. 2009;73:1478–84.PubMedCrossRef Dalgas U, Stenager E, Jakobsen J, et al. Resistance training improves muscle strength and functional capacity in multiple sclerosis. Neurology. 2009;73:1478–84.PubMedCrossRef
25.
Zurück zum Zitat Gutierrez GM, Chow JW, Tillman MD, et al. Resistance training improves gait kinematics in persons with multiple sclerosis. Arch Phys Med Rehabil. 2005;86:1824–9.PubMedCrossRef Gutierrez GM, Chow JW, Tillman MD, et al. Resistance training improves gait kinematics in persons with multiple sclerosis. Arch Phys Med Rehabil. 2005;86:1824–9.PubMedCrossRef
26.
Zurück zum Zitat Giesser B, Beres-Jones J, Budovitch A, Herlihy E, Harkema S. Locomotor training using body weight support on a treadmill improves mobility in persons with multiple sclerosis: a pilot study. Mult Scler. 2007;13:224–31.PubMedCrossRef Giesser B, Beres-Jones J, Budovitch A, Herlihy E, Harkema S. Locomotor training using body weight support on a treadmill improves mobility in persons with multiple sclerosis: a pilot study. Mult Scler. 2007;13:224–31.PubMedCrossRef
27.
Zurück zum Zitat van den Berg M, Dawes H, Wade DT, et al. Treadmill training for individuals with multiple sclerosis: a pilot randomised trial. J Neurol Neurosurg Psychiatry. 2006;77:531–3.PubMedCrossRef van den Berg M, Dawes H, Wade DT, et al. Treadmill training for individuals with multiple sclerosis: a pilot randomised trial. J Neurol Neurosurg Psychiatry. 2006;77:531–3.PubMedCrossRef
28.
Zurück zum Zitat Sutliff MH, Naft JM, Stough DK, et al. Efficacy and safety of a hip flexion assist orthosis in ambulatory multiple sclerosis patients. Arch Phys Med Rehabil. 2008;89:1611–7.PubMedCrossRef Sutliff MH, Naft JM, Stough DK, et al. Efficacy and safety of a hip flexion assist orthosis in ambulatory multiple sclerosis patients. Arch Phys Med Rehabil. 2008;89:1611–7.PubMedCrossRef
29.
Zurück zum Zitat Kim CM, Eng JJ, Whittaker MW. Effects of a simple functional electric system and/or a hinged ankle-foot orthosis on walking in persons with incomplete spinal cord injury. Arch Phys Med Rehabil. 2004;85:1718–23.PubMedCrossRef Kim CM, Eng JJ, Whittaker MW. Effects of a simple functional electric system and/or a hinged ankle-foot orthosis on walking in persons with incomplete spinal cord injury. Arch Phys Med Rehabil. 2004;85:1718–23.PubMedCrossRef
30.
Zurück zum Zitat Paul L, Rafferty D, Young S, et al. The effect of functional electrical stimulation on the physiological cost of gait in people with multiple sclerosis. Mult Scler. 2008;14:954–61.PubMedCrossRef Paul L, Rafferty D, Young S, et al. The effect of functional electrical stimulation on the physiological cost of gait in people with multiple sclerosis. Mult Scler. 2008;14:954–61.PubMedCrossRef
31.
Zurück zum Zitat Barrett CL, Mann GE, Taylor PN, Strike P. A randomized trial to investigate the effects of functional electrical stimulation and therapeutic exercise on walking performance for people with multiple sclerosis. Mult Scler. 2009;15:493–504.PubMedCrossRef Barrett CL, Mann GE, Taylor PN, Strike P. A randomized trial to investigate the effects of functional electrical stimulation and therapeutic exercise on walking performance for people with multiple sclerosis. Mult Scler. 2009;15:493–504.PubMedCrossRef
32.
Zurück zum Zitat Shakespeare DT, Boggild M, Young C (2003) Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 001332 Shakespeare DT, Boggild M, Young C (2003) Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 001332
33.
Zurück zum Zitat Paisley S, Beard S, Hunn A, Wight J. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review. Mult Scler. 2002;8:319–29.PubMedCrossRef Paisley S, Beard S, Hunn A, Wight J. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review. Mult Scler. 2002;8:319–29.PubMedCrossRef
34.
Zurück zum Zitat Orsnes GB, Sørensen PS, Larsen TK, Ravnborg M. Effect of baclofen on gait in spastic MS patients. Acta Neurol Scand. 2000;101:244–8.PubMedCrossRef Orsnes GB, Sørensen PS, Larsen TK, Ravnborg M. Effect of baclofen on gait in spastic MS patients. Acta Neurol Scand. 2000;101:244–8.PubMedCrossRef
35.
Zurück zum Zitat Ben Smail D, Peskine A, Roche N, Mailhan L, Thiébaut I, Bussel B. Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients. Mult Scler. 2006;12:101–3.PubMedCrossRef Ben Smail D, Peskine A, Roche N, Mailhan L, Thiébaut I, Bussel B. Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients. Mult Scler. 2006;12:101–3.PubMedCrossRef
36.
Zurück zum Zitat Bethoux FA, Miller DM, Stough D. Intrathecal baclofen therapy in ambulatory patients with multiple sclerosis: effect on gait speed. Arch Phys Med Rehabil. 2003;84:E10.CrossRef Bethoux FA, Miller DM, Stough D. Intrathecal baclofen therapy in ambulatory patients with multiple sclerosis: effect on gait speed. Arch Phys Med Rehabil. 2003;84:E10.CrossRef
37.
Zurück zum Zitat Jost WH. Botulinum toxin in multiple sclerosis. J Neurol. 2006;253:16–20.CrossRef Jost WH. Botulinum toxin in multiple sclerosis. J Neurol. 2006;253:16–20.CrossRef
38.
Zurück zum Zitat Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry. 2000;68:707–12.PubMedCrossRef Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry. 2000;68:707–12.PubMedCrossRef
39.
Zurück zum Zitat Smania N, Picelli A, Munari D, et al. Rehabilitation procedures in the management of spasticity. Eur J Phys Rehabil Med. 2010;46:423–38.PubMed Smania N, Picelli A, Munari D, et al. Rehabilitation procedures in the management of spasticity. Eur J Phys Rehabil Med. 2010;46:423–38.PubMed
40.
Zurück zum Zitat Sosnoff J, Motl RW, Snook EM, Wynn D. Effect of a 4-week period of unloaded leg cycling exercise on spasticity in multiple sclerosis. NeuroRehabilitation. 2009;24:327–31.PubMed Sosnoff J, Motl RW, Snook EM, Wynn D. Effect of a 4-week period of unloaded leg cycling exercise on spasticity in multiple sclerosis. NeuroRehabilitation. 2009;24:327–31.PubMed
41.
Zurück zum Zitat Sosnoff JJ, Motl RW. Effect of acute unloaded arm versus leg cycling exercise on the soleus H-reflex in adults with multiple sclerosis. Neurosci Lett. 2010;479:307–11.PubMedCrossRef Sosnoff JJ, Motl RW. Effect of acute unloaded arm versus leg cycling exercise on the soleus H-reflex in adults with multiple sclerosis. Neurosci Lett. 2010;479:307–11.PubMedCrossRef
42.
Zurück zum Zitat Katalinic OM, Harvey LA, Herbert RD. Effectiveness of stretch for the treatment and prevention of contractures in people with neurological conditions: a systematic review. Phys Ther. 2011;91:11–24.PubMedCrossRef Katalinic OM, Harvey LA, Herbert RD. Effectiveness of stretch for the treatment and prevention of contractures in people with neurological conditions: a systematic review. Phys Ther. 2011;91:11–24.PubMedCrossRef
43.
Zurück zum Zitat Giovannelli M, Borriello G, Castri P, Prosperini L, Pozzilli C. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil. 2007;21:331–7.PubMedCrossRef Giovannelli M, Borriello G, Castri P, Prosperini L, Pozzilli C. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil. 2007;21:331–7.PubMedCrossRef
44.
Zurück zum Zitat • Sabapathy NM, Minahan CL, Turner GT, Broadley SA. Comparing endurance- and resistance-exercise training in people with multiple sclerosis: a randomized pilot study. Clin Rehabil. 2011;25:14–24. This small randomized pilot study demonstrates that both endurance and resistance exercise training improve balance and walking and health-related quality of life in adults with MS, without exacerbating fatigue.PubMedCrossRef • Sabapathy NM, Minahan CL, Turner GT, Broadley SA. Comparing endurance- and resistance-exercise training in people with multiple sclerosis: a randomized pilot study. Clin Rehabil. 2011;25:14–24. This small randomized pilot study demonstrates that both endurance and resistance exercise training improve balance and walking and health-related quality of life in adults with MS, without exacerbating fatigue.PubMedCrossRef
45.
Zurück zum Zitat Cattaneo D, Jonsdottir J, Zocchi M, Regola A. Effects of balance exercises on people with multiple sclerosis: a pilot study. Clin Rehabil. 2007;21:771–81.PubMedCrossRef Cattaneo D, Jonsdottir J, Zocchi M, Regola A. Effects of balance exercises on people with multiple sclerosis: a pilot study. Clin Rehabil. 2007;21:771–81.PubMedCrossRef
46.
Zurück zum Zitat Widener GL, Allen DD, Gibson-Horn C. Balance-based torso-weighting is effective in improving function in a randomized clinical trial of people with multiple sclerosis. J Neuro Phys Ther. 2007;31:219. Widener GL, Allen DD, Gibson-Horn C. Balance-based torso-weighting is effective in improving function in a randomized clinical trial of people with multiple sclerosis. J Neuro Phys Ther. 2007;31:219.
47.
Zurück zum Zitat Fulk GD. Locomotor training and virtual reality-based balance training for an individual with multiple sclerosis: a case report. J Neurol Phys Ther. 2005;29:34–42.PubMed Fulk GD. Locomotor training and virtual reality-based balance training for an individual with multiple sclerosis: a case report. J Neurol Phys Ther. 2005;29:34–42.PubMed
48.
Zurück zum Zitat Prosperini L, Leonardi L, De Carli P, Mannocchi ML, Pozzilli C. Visuo-proprioceptive training reduces risk of falls in patients with multiple sclerosis. Mult Scler. 2010;16:491–9.PubMedCrossRef Prosperini L, Leonardi L, De Carli P, Mannocchi ML, Pozzilli C. Visuo-proprioceptive training reduces risk of falls in patients with multiple sclerosis. Mult Scler. 2010;16:491–9.PubMedCrossRef
49.
Zurück zum Zitat Goodman AD, Brown TR, Cohen JA, et al. Dose comparison trial of sustained-release fampridine in multiple-sclerosis. Neurology. 2008;71:1134–41.PubMedCrossRef Goodman AD, Brown TR, Cohen JA, et al. Dose comparison trial of sustained-release fampridine in multiple-sclerosis. Neurology. 2008;71:1134–41.PubMedCrossRef
50.
Zurück zum Zitat • Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373:732–8. This multi-center, randomized, controlled, phase III trial demonstrates that dalfampridine improves walking speed approximately 25% in about 33% of patients with MS and slowed walking (25 foot timed walk >8 seconds). PubMedCrossRef • Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373:732–8. This multi-center, randomized, controlled, phase III trial demonstrates that dalfampridine improves walking speed approximately 25% in about 33% of patients with MS and slowed walking (25 foot timed walk >8 seconds). PubMedCrossRef
Metadaten
Titel
Gait Abnormalities in Multiple Sclerosis: Pathogenesis, Evaluation, and Advances in Treatment
verfasst von
Michelle H. Cameron
Joanne M. Wagner
Publikationsdatum
01.10.2011
Verlag
Current Science Inc.
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 5/2011
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-011-0214-y

Weitere Artikel der Ausgabe 5/2011

Current Neurology and Neuroscience Reports 5/2011 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.